Pabolizumab (100mg/4ml) was approved in China at a price of around seventeen thousand dollars.
Pabolizumab was approved by the State Drug Administration of China in November 2019 for the first-line treatment of metastatic squamous non-small cell lung cancer in combination with paclitaxel and carboplatin, but so far it has not yet entered the medical insurance, and the approved price in China is around seventeen thousand yuan, and the specific price is recommended to consult the local hospital or regular pharmacy.
Paborizumab may have cough, nausea, diarrhea, fatigue, thyroid disease, autoimmune pneumonia, autoimmune hepatitis and other side effects during the medication process, it is prohibited for those who are allergic to it, and women of childbearing age should take contraception during the use of the drug.
Paborizumab belongs to the immunosuppressant of anti-tumor therapy, which requires doctors to strictly grasp the indications and monitor adverse reactions, so it must be applied under the guidance of doctors, and must not be applied on its own.